Imago BioSciences (IMGO) 10-Q 12 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Aug. 05, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Entity Registrant Name	Imago BioSciences, Inc.
Entity Central Index Key	0001623715
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity File Number	001-40604
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-4915810
Entity Address, Address Line One	329 Oyster Point Blvd.
Entity Address, Address Line Two	3rd Floor
Entity Address, City or Town	South San Francisco
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94080
City Area Code	415
Local Phone Number	529-5055
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		33,741,648
Document Quarterly Report	true
Document Transition Report	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	IMGO
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 22,772	$ 11,226
Short-term investments	167,238	206,184
Prepaid expenses and other current assets	2,562	3,894
Total current assets	192,572	221,304
Property and equipment, net	3	2
Other long-term assets	3,536	3,480
Total assets	196,111	224,786
Current liabilities:
Accounts payable	2,584	3,459
Accrued and other current liabilities	6,189	6,633
Total current liabilities	8,773	10,092
Commitments and contingencies (Note 6)
Stockholders' equity (deficit):
Common stock, $0.0001 par value; 300,000,000 shares authorized as of both June 30, 2022; and December 31, 2021; 33,737,873 and 33,531,743 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	3	3
Additional paid-in capital	330,951	327,387
Accumulated other comprehensive loss	(828)	(43)
Accumulated deficit	(142,788)	(112,653)
Total stockholders' equity	187,338	214,694
Total liabilities and stockholders' equity	$ 196,111	$ 224,786

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Common stock, par value per share	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock shares issued	33,737,873	33,531,743
Common stock shares outstanding	33,737,873	33,531,743

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 9,677	$ 7,099	$ 22,179	$ 11,871
General and administrative	4,339	1,743	8,350	4,119
Total operating expenses	14,016	8,842	30,529	15,990
Loss from operations	(14,016)	(8,842)	(30,529)	(15,990)
Other income (expense), net:
Interest income	148	82	212	169
Other income (expense), net	127	(46)	182	(94)
Total other income, net	275	36	394	75
Net loss	$ (13,741)	$ (8,806)	$ (30,135)	$ (15,915)
Net loss per share, basic	$ (0.41)	$ (8.13)	$ (0.89)	$ (15.06)
Net loss per share, diluted	$ (0.41)	$ (8.13)	$ (0.89)	$ (15.06)
Weighted-average shares used in computing net loss per share, basic	33,735,785	1,082,932	33,691,163	1,056,624
Weighted-average shares used in computing net loss per share, diluted	33,735,785	1,082,932	33,691,163	1,056,624

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement of Comprehensive Income [Abstract]
Net loss	$ (13,741)	$ (8,806)	$ (30,135)	$ (15,915)
Other comprehensive loss:
Unrealized (loss) gain on available-for-sale securities	(192)	8	(785)	20
Comprehensive loss	$ (13,933)	$ (8,798)	$ (30,920)	$ (15,895)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit	Convertible Preferred Stock
Temporary equity, beginning balance, shares at Dec. 31, 2020						21,435,632
Temporary equity, beginning balance at Dec. 31, 2020						$ 162,612
Beginning balance, shares at Dec. 31, 2020		1,030,023
Beginning balance at Dec. 31, 2020	$ (68,784)		$ 1,561	$ (3)	$ (70,342)
Stock-based compensation	319		319
Other comprehensive income (loss)	12			12
Net loss	(7,109)				(7,109)
Temporary equity, ending balance, shares at Mar. 31, 2021						21,435,632
Temporary equity, ending balance at Mar. 31, 2021						$ 162,612
Ending balance, shares at Mar. 31, 2021		1,030,023
Ending balance at Mar. 31, 2021	(75,562)		1,880	9	(77,451)
Temporary equity, beginning balance, shares at Dec. 31, 2020						21,435,632
Temporary equity, beginning balance at Dec. 31, 2020						$ 162,612
Beginning balance, shares at Dec. 31, 2020		1,030,023
Beginning balance at Dec. 31, 2020	(68,784)		1,561	(3)	(70,342)
Other comprehensive income (loss)	20
Net loss	(15,915)
Temporary equity, ending balance, shares at Jun. 30, 2021						21,435,632
Temporary equity, ending balance at Jun. 30, 2021						$ 162,612
Ending balance, shares at Jun. 30, 2021		1,087,059
Ending balance at Jun. 30, 2021	(83,819)		2,421	17	(86,257)
Temporary equity, beginning balance, shares at Mar. 31, 2021						21,435,632
Temporary equity, beginning balance at Mar. 31, 2021						$ 162,612
Beginning balance, shares at Mar. 31, 2021		1,030,023
Beginning balance at Mar. 31, 2021	(75,562)		1,880	9	(77,451)
Exercise of stock options, shares		57,036
Exercise of stock options	107		107
Stock-based compensation	434		434
Other comprehensive income (loss)	8			8
Net loss	(8,806)				(8,806)
Temporary equity, ending balance, shares at Jun. 30, 2021						21,435,632
Temporary equity, ending balance at Jun. 30, 2021						$ 162,612
Ending balance, shares at Jun. 30, 2021		1,087,059
Ending balance at Jun. 30, 2021	$ (83,819)		2,421	17	(86,257)
Beginning balance, shares at Dec. 31, 2021	33,531,743	33,531,743
Beginning balance at Dec. 31, 2021	$ 214,694	$ 3	327,387	(43)	(112,653)
Exercise of stock options, shares		201,940
Exercise of stock options	454		454
Stock-based compensation	1,351		1,351
Other comprehensive income (loss)	(593)			(593)
Net loss	(16,394)				(16,394)
Ending balance, shares at Mar. 31, 2022		33,733,683
Ending balance at Mar. 31, 2022	$ 199,512	$ 3	329,192	(636)	(129,047)
Beginning balance, shares at Dec. 31, 2021	33,531,743	33,531,743
Beginning balance at Dec. 31, 2021	$ 214,694	$ 3	327,387	(43)	(112,653)
Other comprehensive income (loss)	(785)
Net loss	$ (30,135)
Ending balance, shares at Jun. 30, 2022	33,737,873	33,737,873
Ending balance at Jun. 30, 2022	$ 187,338	$ 3	330,951	(828)	(142,788)
Beginning balance, shares at Mar. 31, 2022		33,733,683
Beginning balance at Mar. 31, 2022	199,512	$ 3	329,192	(636)	(129,047)
Exercise of stock options, shares		4,190
Exercise of stock options	17		17
Stock-based compensation	1,742		1,742
Other comprehensive income (loss)	(192)			(192)
Net loss	$ (13,741)				(13,741)
Ending balance, shares at Jun. 30, 2022	33,737,873	33,737,873
Ending balance at Jun. 30, 2022	$ 187,338	$ 3	$ 330,951	$ (828)	$ (142,788)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (30,135)	$ (15,915)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	3,093	753
Amortization of premium and discounts on available-for-sale investments	(200)	92
Depreciation and amortization	2	4
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,332	(345)
Other long-term assets	28	293
Accounts payable	(875)	585
Accrued expenses and other current liabilities	(531)	286
Net cash used in operating activities	(27,286)	(14,247)
Cash flows from investing activities:
Purchases of available-for-sale investments	(90,799)	(33,701)
Proceeds from maturities of available-for-sale investments	129,160	36,177
Net cash provided by investing activities	38,361	2,476
Cash flows from financing activities:
Proceeds from exercise of stock options	471	107
Payment of deferred offering costs		(1,009)
Net cash provided by (used in) financing activities	471	(902)
Net increase (decrease) in cash and cash equivalents	11,546	(12,673)
Cash and cash equivalents at beginning of period	11,226	19,266
Cash and cash equivalents at end of period	22,772	6,593
Supplemental disclosure of cash information:
Cash paid for taxes	262	39
Supplemental disclosure of non-cash information:
Deferred financing costs included in accrued and other current liabilities	$ 87	$ 419

Organization and Description of

Organization and Description of the Business	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of the Business	1. Organization and Description of the Business Description of the Business Imago BioSciences, Inc., or Imago, or the Company, was incorporated on March 28, 2012 as a Delaware corporation and is headquartered in South San Francisco, California. The Company is a clinical-stage biopharmaceutical company discovering and developing small molecule product candidates that target lysine-specific demethylase 1, or LSD1, an enzyme that plays a central role in the production of blood cells in the bone marrow. The Company is focused on improving the quality of life for patients with cancer and bone marrow diseases in addition to prolonging their lives. The Company’s lead product candidate is bomedemstat for the treatment of myeloproliferative neoplasms, or MPNs, a family of related, chronic cancers of the bone marrow. The three most common MPNs are myelofibrosis, or MF, essential thrombocythemia, or ET, and polycythemia vera, or PV. The Company is pursuing the development of bomedemstat as a potentially disease-modifying therapy in ET and MF to address the limitations of currently approved therapies. In 2021, the Company completed enrollment in a Phase 2 clinical trial of bomedemstat for the treatment of MF and in 2022, the Company completed enrollment in a Phase 2 clinical trial of bomedemstat for the treatment of ET. To enable the collection of long-term safety and pharmacodynamic data, Imago initiated a Phase 2 Extension Study in 2021 into which patients from our Phase 2 clinical trial in MF have transitioned and patients from our Phase 2 clinical trial in ET will be eligible to transition. Initial public offering On July 15, 2021, the Company’s registration statement on Form S-1 (File No. 333-257419), relating to its initial public offering, or the IPO, of common stock became effective. The IPO closed on July 20, 2021 at which time the Company issued an aggregate of 8,400,000 shares of its common stock at a price of $ 16.00 per share. Within 30 days following the close, an additional 1,260,000 shares were issued in connection with the full exercise by the underwriters of their option to purchase additional shares of common stock. In connection with the completion of its IPO, on July 20, 2021 the Company’s certificate of incorporation was amended and restated to provide for 300,000,000 authorized shares of common stock with a par value of $ 0.0001 per share and 10,000,000 authorized shares of preferred stock with a par value of $ 0.0001 per share. The Company received net proceeds of approximately $ 140.5 million from the IPO, after deducting underwriting discounts, commissions and offering costs. Concurrent with the IPO, the Company issued 1,250,000 shares of common stock in a private placement, or the Private Placement, for net proceeds of $ 20.0 million. Immediately prior to the completion of the IPO, all shares of convertible preferred stock then outstanding were converted into 21,435,632 shares of common stock. Liquidity and capital resources The Company has incurred net losses and cash out flows from operations since inception and as of June 30, 2022, has an accumulated deficit of $ 142.8 million. As of June 30, 2022, the Company had cash, cash equivalents and short-term investments of $ 190.0 million, which are available to fund future operations. Management expects to incur additional losses in the future to conduct research and development and recognizes the need to raise capital to fully implement its business plan. The Company has historically financed its operations primarily with the proceeds from the issuance of its convertible preferred stock and to a lesser extent debt financing, in each case prior to the IPO and from sale of shares of common stock in the IPO and the concurrent Private Placement. The Company may raise additional capital through additional equity financings, debt financings or other sources. Based on projected activities, management believes that its existing cash, cash equivalents and short-term investments as of June 30, 2022, will be sufficient to support operations for at least the next 12 months following issuance of these unaudited condensed consolidated financial statements. Reverse stock split On July 13, 2021, the Company effected a reverse stock split of the Company’s common stock on an 8.4 -for-1 basis, or the Reverse Stock Split. In connection with the Reverse Stock Split, all common stock and convertible preferred stock share and per share amounts for all periods presented in these unaudited condensed consolidated financial statements have been retroactively adjusted, to reflect this Reverse Stock Split. Authorized shares and par values were not adjusted. Coronavirus pandemic The Company's management is actively monitoring the global situation for potential effects on the Company's financial condition, liquidity, operations, suppliers, industry and workforce. Given the volatility and evolution of the continuing COVID-19 pandemic and the evolving global responses to curb rates of infection from new strains, such as Omicron, rates of hospitalization and death, and to enhance the global rates of full vaccination and availability of vaccine boosters and COVID-19 treatments, the Company is not able to estimate the effects of the COVID-19 pandemic on its results of operations, financial condition, or liquidity. Although the Company cannot estimate the length or gravity of the impact of the COVID-19 outbreak at this time, if the pandemic continues, it may have a material adverse effect on the Company’s results of operations, financial position and liquidity in 2022.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, certain prepaid assets and accrued liabilities for research and development activities, valuation of deferred tax assets, the fair values of common and convertible preferred stock prior to the IPO and the fair value of stock options. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. Unaudited Condensed Consolidated Financial Statements The unaudited condensed consolidated balance sheet as of June 30, 2022, and the interim condensed consolidated statements of operations, comprehensive loss, and stockholders’ equity for the three and six months ended June 30, 2022, and 2021 and interim condensed consolidated statements of cash flows for the six months ended June 30, 2022, and 2021 are unaudited. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company’s financial position, results of operations and cash flows for the interim periods presented. The financial data and the other financial information disclosed in these notes to the unaudited condensed consolidated financial statements related to the three and six month periods are also unaudited. The condensed results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2021, included herein was derived from the audited consolidated financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 (File No. 001-40604), as filed with the Securities and Exchange Commission, or the SEC, pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs consist of salaries, benefits, and other personnel-related costs, including stock-based compensation, laboratory supplies, clinical studies and related clinical manufacturing costs, fees paid to other entities to conduct certain research and development activities on the Company’s behalf, as well as allocated facility and other related costs. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses until the related goods are delivered or services are performed. The Company estimates preclinical and clinical study research expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical and clinical studies and research services on its behalf. The Company records the costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued and other current liabilities in the unaudited condensed consolidated balance sheets. These costs are a component of the Company’s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued and other current liabilities balance. As actual costs become known, the Company adjusts its accrued expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status and timing of actual services performed have varied and may vary in the future from the Company’s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company’s accrued costs could materially affect the Company’s results of operations. Stock-Based Compensation Stock-based compensation is measured at the grant date for all equity awards granted to employees and non-employees based on the fair value of the awards, including stock options and restricted shares. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes option-pricing model. For stock-based awards that vest subject to the satisfaction of a service requirement, the expense is recognized using the straight-line method over the requisite service period, which is generally the vesting period. Forfeitures are accounted for when they occur. Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of the Company’s common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company is in a loss position for the periods presented, diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive. Comprehensive Loss Comprehensive loss includes net loss and certain changes in stockholders’ equity that are excluded from net loss. The Company’s comprehensive loss is comprised of unrealized gains and losses on the Company’s available-for-sale investments. Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2019-12 , Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , or ASU 2019-12, which is intended to simplify the accounting for income taxes. The guidance eliminates certain exceptions to the approach for intra period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. As an emerging growth company, this new standard was effective for the Company for its fiscal year beginning January 1, 2022. The Company adopted the standard on January 1, 2022 , and the adoption did no t have a material impact on the Company’s consolidated financial statements. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. As an emerging growth company, this new standard will become effective for the Company in the fiscal year beginning January 1, 2023 and must be adopted using a modified retrospective approach, with certain exceptions. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: • Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. • Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. • Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at measurement date. Fair value accounting is applied for all financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). As of June 30, 2022, and December 31, 2021, the carrying amount of prepaid expenses and other current assets, accounts payable and accrued liabilities approximated their estimated fair value due to the short-term nature of these items. The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: June 30, 2022 Level 1 Level 2 Level 3 Fair Value (in thousands) Assets: Money market funds $ 20,281 $ — $ — $ 20,281 Commercial paper — 138,816 — 138,816 U.S. treasury securities — 28,422 — 28,422 Total financial assets $ 20,281 $ 167,238 $ — $ 187,519 December 31, 2021 Level 1 Level 2 Level 3 Fair Value (in thousands) Assets: Money market funds $ 7,794 $ — $ — $ 7,794 Corporate bonds — 4,499 — 4,499 Commercial paper — 187,749 — 187,749 U.S. treasury securities — 16,024 — 16,024 Total financial assets $ 7,794 $ 208,272 $ — $ 216,066 Money market funds are highly liquid investments and are actively traded. The pricing information on the Company’s money market funds is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy. The Company’s short-term investments are classified as cash equivalents if their original maturities are less than three months. The Company’s short-term investments are considered Level 2 financial instruments as their fair values are determined using inputs that are observable in the market or can be derived principally from recently executed transactions, cash flow models with yield curves, and benchmark securities. There were no transfers in or out of Level 3 of the fair value hierarchy during the periods presented.

Investments

Investments	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Investments	4. Investments The following tables summarize the fair value and amortized cost of the Company’s available-for-sale debt securities by major security type: June 30, 2022 Amortized Gross Gross Aggregate (in thousands) Assets: Money market funds $ 20,281 $ — $ — $ 20,281 Commercial paper 139,462 — ( 646 ) 138,816 U.S. treasury securities 28,604 — ( 182 ) 28,422 Total financial assets $ 188,347 $ — $ ( 828 ) $ 187,519 December 31, 2021 Amortized Gross Gross Aggregate (in thousands) Assets: Money market funds $ 7,794 $ — $ — $ 7,794 Corporate bonds 4,500 — ( 1 ) 4,499 Commercial paper 187,789 17 ( 57 ) 187,749 U.S. treasury securities 16,026 — ( 2 ) 16,024 Total financial assets $ 216,109 $ 17 $ ( 60 ) $ 216,066 The following table summarizes the classification of the Company’s available-for-sale debt securities at fair value: June 30, December 31, 2022 2021 (in thousands) Cash equivalents $ 20,281 $ 9,882 Short-term investments 167,238 206,184 Total cash equivalents and short-term investments $ 187,519 $ 216,066 The following table summarizes the fair values of the Company’s available-for-sale debt securities by contractual maturity: June 30, December 31, 2022 2021 (in thousands) Within one year $ 187,519 $ 216,066 Total cash equivalents and short-term investments $ 187,519 $ 216,066 There were no impairments of available-for-sale debt securities considered “other-than-temporary” during the three and six months ended June 30, 2022 as it was more likely than not the Company would hold the securities until maturity or a recovery of the cost basis.

Balance Sheet Components

Balance Sheet Components	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Balance Sheet Components	5. Balance Sheet Components Accrued and Other Current Liabilities Accrued and other current liabilities consist of the following: June 30, December 31, 2022 2021 (in thousands) Accrued research and development $ 3,602 $ 4,213 Compensation and related benefits 2,006 1,881 Accrued professional service fees 217 207 Other 364 332 Total accrued and other current liabilities $ 6,189 $ 6,633

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Operating Leases As of June 30, 2022 and December 31, 2021, the Company has cancellable operating lease agreements with lease terms of less than 12 months. For the three months ended June 30, 2022 and 2021, rent expense was $ 18,000 and $ 20,000 , respectively. For the six months ended June 30, 2022 and 2021, rent expense was $ 40,000 and $ 50,000 , respectively. As of June 30, 2022, the Company has one non-cancellable operating lease with a two-year term that is immaterial. Guarantees and Indemnifications In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of June 30, 2022, and December 31, 2021, the Company does not have any material indemnification claims that were probable or reasonably possible and, consequently, has not recorded related liabilities.

Equity

Equity	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Equity	7. Equity Common Stock The Company reserved the following shares of common stock, on an as-if converted basis, for issuance as follows: June 30, December 31, 2022 2021 Options outstanding under the 2021 Equity Incentive plan 4,392,261 4,028,461 Options available for future grant 3,780,239 2,673,582 Reserved for employee stock purchase plan 685,317 350,000 Total 8,857,817 7,052,043

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation 2012 Equity Incentive Plan In October 2012, the Company adopted the 2012 Equity Incentive Plan, or the 2012 Plan, under which 238,095 shares of the Company’s common stock were initially reserved for issuance to employees, directors and consultants. 2021 Equity Incentive Plan In July 2021, the Company adopted the 2021 Incentive Award Plan, or 2021 Plan, which became effective in connection with the IPO. The 2012 Plan was terminated in connection with the IPO when the 2021 Plan became effective; however, awards granted under the 2012 Plan that remain outstanding continue to be governed by the 2012 Plan. Shares reserved for issuance under the 2012 Plan but not subject to awards as of the date of the IPO were added to the available shares in the 2021 Plan. Shares subject to awards granted under the 2012 Plan that were or are forfeited to the Company, terminated without exercise or repurchased for the original purchase price after the IPO have been and will be added to the shares reserved for issuance under the 2021 Plan. Under the terms of the 2021 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance bonus awards, performance stock unit awards, dividend equivalents awards or other stock or cash-based awards to individuals who are then employees, consultants, or directors of the Company. Under the terms of the 2021 Plan, options may be granted at an exercise price not less than fair market value. For employees holding more than 10 % of the voting rights of all classes of stock, the exercise prices for incentive and non-statutory stock options may not be less than 110 % of fair market value, as determined by the board of directors. The terms of options granted under the 2021 Plan may not exceed ten years . The vesting schedule of newly issued option grants is generally four years . The Company initially reserved 3,450,000 shares of common stock for issuance under the 2021 Plan. The number of shares initially reserved will be increased by (i) any shares available for issuance under the 2012 Plan as of the day before the IPO, (ii) any shares that are subject to the 2012 Plan that become available for issuance under the 2012 Plan and (iii) the annual increase on January 1 of each year, beginning January 1, 2022 , and continuing through and including January 1, 2031 , by 5 % of the shares of common stock outstanding on the last day of the immediately preceding fiscal year, or a lesser number of shares determined by the Company's board of directors. As of June 30, 2022, there were 3,780,239 shares available for grant under the 2021 Plan. 2021 Employee Stock Purchase Plan In July 2021, the Company adopted the Employee Stock Purchase Plan, or the ESPP, which became effective in connection with the IPO. The purpose of the ESPP is to assist employees of the Company in acquiring a stock ownership interest in the Company, to help such employees provide for their future security and to encourage them to remain in the employment of the Company. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Code. The compensation committee of the board of directors administers the Company’s ESPP. The maximum aggregate number of shares of common stock that may be issued pursuant to the exercise of purchase rights under the Company’s ESPP that are granted to employees is 4,703,469 shares. Additionally, the number of shares of common stock reserved for issuance under the Company’s ESPP increases automatically each year, beginning on January 1, 2022 , and continuing through and including January 1, 2031 , by 1 % of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or a lesser number as determined by the board of directors. Shares subject to purchase rights granted under the Company’s ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the Company’s ESPP. As of June 30, 2022, the Company has reserved 685,317 shares of common stock under the ESPP. There are two ESPP offering periods each year and the first offering period started on June 1, 2022. Each offering period has one purchase period which occurs every six months. There were no shares issued under the ESPP during the three and six months ended June 30, 2022. Stock Option Activity Stock option activity under the 2012 Plan and the 2021 Plan was as follows: Options Available for Grant Number of Options Outstanding Weighted-Average Exercise Price Per Share Weighted-Average Aggregate Intrinsic Value (in thousands) Outstanding as of January 1, 2022 2,673,582 4,028,461 $ 8.81 8.40 $ 60,089 Authorized 1,676,587 — — Granted ( 631,520 ) 631,520 17.67 Exercised — ( 206,130 ) 2.29 Cancelled 61,590 ( 61,590 ) 19.65 Outstanding as of June 30, 2022 3,780,239 4,392,261 $ 10.24 8.25 $ 26,189 Exercisable as of June 30, 2022 1,527,275 $ 3.58 6.71 $ 15,328 The aggregate intrinsic values of options outstanding and exercisable were calculated as the difference between the exercise price of the options and the closing price of the Company’s common stock of $ 13.39 as of June 30, 2022. The total intrinsic value of options exercised during the three and six months ended June 30, 2022 was $ 0.1 million and $ 3.9 million, respectively. The total intrinsic value of options exercised during the three and six months ended June 30, 2021 was $ 0.3 million. Such intrinsic value of options exercised is the difference between the fair value of Company’s common stock at the time of exercise and the exercise price of the stock option. The weighted-average grant-date fair value per share for stock options granted during the three months ended June 30, 2022 and 2021 was $ 9.88 and $ 4.21 , respectively. The weighted-average grant-date fair value per share for stock options granted during the six months ended June 30, 2022 and 2021 was $ 12.10 and $ 2.82 , respectively. Determining Fair Value The estimated grant-date fair value of the Company’s stock options was calculated using the Black-Scholes option pricing model, based on the following assumptions: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Expected term (in years) 5.5 - 6.1 6.1 5.5 - 6.1 5.9 - 6.1 Expected volatility 77.1 % 67.7 % 77.1 % - 78.1 % 67.7 % - 69.9 % Risk-free interest rate 2.8 % - 3.3 % 1.0 % 1.7 % - 3.3 % 0.6 % - 1.1 % Expected dividend yield —% —% —% —% Each of these inputs is subjective and generally requires significant judgment. Expected Term —The expected term represents the period that the Company’s stock-based awards are expected to be outstanding and is determined using the simplified method, which is based on the mid-point between the contractual term and vesting period. Volatility —The Company determines volatility based on the historical volatilities of comparable publicly traded life science companies over a period equal to the expected term because it does not have sufficient trading history for its common stock price. The comparable companies were chosen based on the similar size, stage in the life cycle, or area of specialty. The Company will continue to apply this process until sufficient historical information regarding volatility on its own stock becomes available. Risk-Free Interest Rate —The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Dividend Yield —The Company has never paid and has no plans to pay any dividends on its common stock. Therefore, the Company has used an expected dividend yield of zero . Stock-Based Compensation Total stock-based compensation recognized for the periods presented is as follows: Three Months Ended Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 710 $ 131 $ 1,363 $ 188 General and administrative 1,032 303 1,730 565 Total stock-based compensation expense $ 1,742 $ 434 $ 3,093 $ 753 As of June 30, 2022, total unrecognized stock-based compensation expense is approximately $ 22.5 million, related to unvested stock options to be recognized over the remaining weighted-average vesting period of 2.9 years.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes For the three and six months ended June 30, 2022 and 2021, the Company did no t record any income tax expense. The U.S. federal and state deferred tax assets generated from the Company’s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	10. Net Loss Per Share The following potentially dilutive shares, including all outstanding stock options, were excluded from the calculation of diluted shares outstanding for the periods presented as the effect would have been anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Convertible preferred stock — 21,435,632 — 21,435,632 Outstanding stock options 4,392,261 3,171,061 4,392,261 3,171,061 Total 4,392,261 24,606,693 4,392,261 24,606,693

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events The Company did not have any subsequent events as of the filing date of this Quarterly Report on Form 10-Q.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, certain prepaid assets and accrued liabilities for research and development activities, valuation of deferred tax assets, the fair values of common and convertible preferred stock prior to the IPO and the fair value of stock options. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.
Unaudited Condensed Consolidated Financial Statements	Unaudited Condensed Consolidated Financial Statements The unaudited condensed consolidated balance sheet as of June 30, 2022, and the interim condensed consolidated statements of operations, comprehensive loss, and stockholders’ equity for the three and six months ended June 30, 2022, and 2021 and interim condensed consolidated statements of cash flows for the six months ended June 30, 2022, and 2021 are unaudited. These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company’s annual consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting only of normal recurring adjustments) that are necessary for the fair statement of the Company’s financial position, results of operations and cash flows for the interim periods presented. The financial data and the other financial information disclosed in these notes to the unaudited condensed consolidated financial statements related to the three and six month periods are also unaudited. The condensed results of operations for the three and six months ended June 30, 2022, are not necessarily indicative of the results to be expected for the year ending December 31, 2022, or for any other future annual or interim period. The condensed consolidated balance sheet as of December 31, 2021, included herein was derived from the audited consolidated financial statements as of that date. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 (File No. 001-40604), as filed with the Securities and Exchange Commission, or the SEC, pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred. Research and development costs consist of salaries, benefits, and other personnel-related costs, including stock-based compensation, laboratory supplies, clinical studies and related clinical manufacturing costs, fees paid to other entities to conduct certain research and development activities on the Company’s behalf, as well as allocated facility and other related costs. Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized as prepaid expenses until the related goods are delivered or services are performed. The Company estimates preclinical and clinical study research expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical and clinical studies and research services on its behalf. The Company records the costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in accrued and other current liabilities in the unaudited condensed consolidated balance sheets. These costs are a component of the Company’s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued and other current liabilities balance. As actual costs become known, the Company adjusts its accrued expenses. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status and timing of actual services performed have varied and may vary in the future from the Company’s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company’s accrued costs could materially affect the Company’s results of operations.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation is measured at the grant date for all equity awards granted to employees and non-employees based on the fair value of the awards, including stock options and restricted shares. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes option-pricing model. For stock-based awards that vest subject to the satisfaction of a service requirement, the expense is recognized using the straight-line method over the requisite service period, which is generally the vesting period. Forfeitures are accounted for when they occur.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of the Company’s common stock outstanding for the period, without consideration for potential dilutive shares of common stock. As the Company is in a loss position for the periods presented, diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive.
Comprehensive Loss	Comprehensive Loss Comprehensive loss includes net loss and certain changes in stockholders’ equity that are excluded from net loss. The Company’s comprehensive loss is comprised of unrealized gains and losses on the Company’s available-for-sale investments.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2019-12 , Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes , or ASU 2019-12, which is intended to simplify the accounting for income taxes. The guidance eliminates certain exceptions to the approach for intra period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. As an emerging growth company, this new standard was effective for the Company for its fiscal year beginning January 1, 2022. The Company adopted the standard on January 1, 2022 , and the adoption did no t have a material impact on the Company’s consolidated financial statements.
Recent Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments , which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. As an emerging growth company, this new standard will become effective for the Company in the fiscal year beginning January 1, 2023 and must be adopted using a modified retrospective approach, with certain exceptions. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values: June 30, 2022 Level 1 Level 2 Level 3 Fair Value (in thousands) Assets: Money market funds $ 20,281 $ — $ — $ 20,281 Commercial paper — 138,816 — 138,816 U.S. treasury securities — 28,422 — 28,422 Total financial assets $ 20,281 $ 167,238 $ — $ 187,519 December 31, 2021 Level 1 Level 2 Level 3 Fair Value (in thousands) Assets: Money market funds $ 7,794 $ — $ — $ 7,794 Corporate bonds — 4,499 — 4,499 Commercial paper — 187,749 — 187,749 U.S. treasury securities — 16,024 — 16,024 Total financial assets $ 7,794 $ 208,272 $ — $ 216,066

Investments (Tables)

Investments (Tables)	6 Months Ended
	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Summary of Available-For-Sale Debt Securities	The following tables summarize the fair value and amortized cost of the Company’s available-for-sale debt securities by major security type: June 30, 2022 Amortized Gross Gross Aggregate (in thousands) Assets: Money market funds $ 20,281 $ — $ — $ 20,281 Commercial paper 139,462 — ( 646 ) 138,816 U.S. treasury securities 28,604 — ( 182 ) 28,422 Total financial assets $ 188,347 $ — $ ( 828 ) $ 187,519 December 31, 2021 Amortized Gross Gross Aggregate (in thousands) Assets: Money market funds $ 7,794 $ — $ — $ 7,794 Corporate bonds 4,500 — ( 1 ) 4,499 Commercial paper 187,789 17 ( 57 ) 187,749 U.S. treasury securities 16,026 — ( 2 ) 16,024 Total financial assets $ 216,109 $ 17 $ ( 60 ) $ 216,066
Summary of Available-For-Sale Debt Securities at Fair Value	The following table summarizes the classification of the Company’s available-for-sale debt securities at fair value: June 30, December 31, 2022 2021 (in thousands) Cash equivalents $ 20,281 $ 9,882 Short-term investments 167,238 206,184 Total cash equivalents and short-term investments $ 187,519 $ 216,066
Summary of Fair Value of Available-For-Sale Debt Securities by Contractual Maturity	The following table summarizes the fair values of the Company’s available-for-sale debt securities by contractual maturity: June 30, December 31, 2022 2021 (in thousands) Within one year $ 187,519 $ 216,066 Total cash equivalents and short-term investments $ 187,519 $ 216,066

Balance Sheet Components (Table

Balance Sheet Components (Tables)	6 Months Ended
	Jun. 30, 2022
Payables and Accruals [Abstract]
Summary of Accrued and Other Current Liabilities	Accrued and other current liabilities consist of the following: June 30, December 31, 2022 2021 (in thousands) Accrued research and development $ 3,602 $ 4,213 Compensation and related benefits 2,006 1,881 Accrued professional service fees 217 207 Other 364 332 Total accrued and other current liabilities $ 6,189 $ 6,633

Equity (Tables)

Equity (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Schedule of Common Stock Shares Reserved for Issuance	The Company reserved the following shares of common stock, on an as-if converted basis, for issuance as follows: June 30, December 31, 2022 2021 Options outstanding under the 2021 Equity Incentive plan 4,392,261 4,028,461 Options available for future grant 3,780,239 2,673,582 Reserved for employee stock purchase plan 685,317 350,000 Total 8,857,817 7,052,043

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The estimated grant-date fair value of the Company’s stock options was calculated using the Black-Scholes option pricing model, based on the following assumptions: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Expected term (in years) 5.5 - 6.1 6.1 5.5 - 6.1 5.9 - 6.1 Expected volatility 77.1 % 67.7 % 77.1 % - 78.1 % 67.7 % - 69.9 % Risk-free interest rate 2.8 % - 3.3 % 1.0 % 1.7 % - 3.3 % 0.6 % - 1.1 % Expected dividend yield —% —% —% —%
Schedule of Stock-based Compensation Expense	Total stock-based compensation recognized for the periods presented is as follows: Three Months Ended Six Months Ended June 30, 2022 2021 2022 2021 Research and development $ 710 $ 131 $ 1,363 $ 188 General and administrative 1,032 303 1,730 565 Total stock-based compensation expense $ 1,742 $ 434 $ 3,093 $ 753
2012 and 2021 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Schedule of Stock Option Activity	Stock option activity under the 2012 Plan and the 2021 Plan was as follows: Options Available for Grant Number of Options Outstanding Weighted-Average Exercise Price Per Share Weighted-Average Aggregate Intrinsic Value (in thousands) Outstanding as of January 1, 2022 2,673,582 4,028,461 $ 8.81 8.40 $ 60,089 Authorized 1,676,587 — — Granted ( 631,520 ) 631,520 17.67 Exercised — ( 206,130 ) 2.29 Cancelled 61,590 ( 61,590 ) 19.65 Outstanding as of June 30, 2022 3,780,239 4,392,261 $ 10.24 8.25 $ 26,189 Exercisable as of June 30, 2022 1,527,275 $ 3.58 6.71 $ 15,328

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Potentially Dilutive Shares Including All Outstanding Stock Options Were Not Included in Calculation of Diluted Shares Outstanding	The following potentially dilutive shares, including all outstanding stock options, were excluded from the calculation of diluted shares outstanding for the periods presented as the effect would have been anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2022 2021 2022 2021 Convertible preferred stock — 21,435,632 — 21,435,632 Outstanding stock options 4,392,261 3,171,061 4,392,261 3,171,061 Total 4,392,261 24,606,693 4,392,261 24,606,693

Organization and Description _2

Organization and Description of the Business - Additional Information (Details) $ / shares in Units, $ in Thousands			6 Months Ended
	Jul. 20, 2021 USD ($) $ / shares shares	Jul. 13, 2021	Jun. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares	Aug. 20, 2021 shares
Organization And Description Of Business [Line Items]
Common stock shares issued			33,737,873	33,531,743
Sale of stock price per share | $ / shares			$ 13.39
Common stock shares authorized			300,000,000	300,000,000
Common stock, par value per share | $ / shares			$ 0.0001	$ 0.0001
Accumulated deficit | $			$ 142,788	$ 112,653
Cash, cash equivalents and short-term investments | $			$ 190,000
Reverse stock split			common stock on an 8.4-for-1 basis, or the Reverse Stock Split.
Reverse stock split conversion ratio		0.119048
IPO
Organization And Description Of Business [Line Items]
Common stock shares issued	8,400,000
Sale of stock price per share | $ / shares	$ 16
Proceeds from issuance of common stock | $	$ 140,500
Common stock shares authorized	300,000,000
Common stock, par value per share | $ / shares	$ 0.0001
Preferred stock, authorized	10,000,000
Preferred stock, par value per share | $ / shares	$ 0.0001
IPO | Common Stock
Organization And Description Of Business [Line Items]
Convertible preferred stock converted into shares of common stock	21,435,632
Private Placement
Organization And Description Of Business [Line Items]
Common stock shares issued	1,250,000
Proceeds from issuance of common stock | $	$ 20,000
Underwriters Option to Purchase Additional Shares
Organization And Description Of Business [Line Items]
Common stock shares issued					1,260,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details)	6 Months Ended
	Jun. 30, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Accounting Standards Update [Extensible Enumeration]	us-gaap:AccountingStandardsUpdate201912Member
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update immaterial effect [true false]	true

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Assets:
Financial assets	$ 187,519	$ 216,066
Corporate Bonds
Assets:
Financial assets		4,499
Money Market Funds
Assets:
Financial assets	20,281	7,794
Commercial Paper
Assets:
Financial assets	138,816	187,749
U.S. Treasury Securities
Assets:
Financial assets	28,422	16,024
Level 1
Assets:
Financial assets	20,281	7,794
Level 1 | Money Market Funds
Assets:
Financial assets	20,281	7,794
Level 2
Assets:
Financial assets	167,238	208,272
Level 2 | Corporate Bonds
Assets:
Financial assets		4,499
Level 2 | Commercial Paper
Assets:
Financial assets	138,816	187,749
Level 2 | U.S. Treasury Securities
Assets:
Financial assets	$ 28,422	$ 16,024

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Fair value, transfers into level 3	$ 0	$ 0
Fair value, transfers out of level 3	$ 0	$ 0

Investments - Summary of Availa

Investments - Summary of Available-For-Sale Debt Securities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 188,347	$ 216,109
Gross Unrealized Gains		17
Gross Unrealized Losses	(828)	(60)
Aggregate Fair Value	187,519	216,066
Money Market Funds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	20,281	7,794
Aggregate Fair Value	20,281	7,794
Corporate Bonds
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		4,500
Gross Unrealized Losses		(1)
Aggregate Fair Value		4,499
Commercial Paper
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	139,462	187,789
Gross Unrealized Gains		17
Gross Unrealized Losses	(646)	(57)
Aggregate Fair Value	138,816	187,749
U.S. Treasury Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	28,604	16,026
Gross Unrealized Losses	(182)	(2)
Aggregate Fair Value	$ 28,422	$ 16,024

Investments - Summary of Avai_2

Investments - Summary of Available-For-Sale Debt Securities at Fair Value (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Cash equivalents	$ 20,281	$ 9,882
Short-term investments	167,238	206,184
Total cash equivalents and short-term investments	$ 187,519	$ 216,066

Investments - Summary of Fair V

Investments - Summary of Fair Value of Available-For-Sale Debt Securities by Contractual Maturity (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Within one year	$ 187,519	$ 216,066
Total cash equivalents and short-term investments	$ 187,519	$ 216,066

Investments - Additional Inform

Investments - Additional Information (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]
Other-than-temporary, available-for-sale debt securities	$ 0	$ 0

Balance Sheet Components - Summ

Balance Sheet Components - Summary of Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued research and development	$ 3,602	$ 4,213
Compensation and related benefits	2,006	1,881
Accrued professional service expenses	217	207
Other	364	332
Total accrued and other current liabilities	$ 6,189	$ 6,633

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($) Lease	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) Lease	Jun. 30, 2021 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Rent expense | $	$ 18,000	$ 20,000	$ 40,000	$ 50,000
Number of non-cancellable operating lease | Lease	1		1
Operating lease term	2 years		2 years

Equity - Schedule of Common Sto

Equity - Schedule of Common Stock Shares Reserved for Issuance (Details) - shares	Jun. 30, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Common stock, initially reserved for issuance	8,857,817	7,052,043
Options Outstanding under 2021 Equity Incentive plan
Class Of Stock [Line Items]
Common stock, initially reserved for issuance	4,392,261	4,028,461
Options Available for Future Grant
Class Of Stock [Line Items]
Common stock, initially reserved for issuance	3,780,239	2,673,582
Reserved for Employee Stock Purchase Plan
Class Of Stock [Line Items]
Common stock, initially reserved for issuance	685,317	350,000

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Oct. 31, 2012
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, initially reserved for issuance		8,857,817		8,857,817		7,052,043
Common stock price per share		$ 13.39		$ 13.39
Total intrinsic value of options exercised		$ 0.1	$ 0.3	$ 3.9	$ 0.3
Weighted average grant date fair value for stock options granted		$ 9.88	$ 4.21	$ 12.10	$ 2.82
Expected dividend yield				0%
Total unrecognized stock-based compensation expense		$ 22.5		$ 22.5
Weighted-average vesting period of unvested stock options				2 years 10 months 24 days
2012 Plan | Employees, Directors and Consultants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, initially reserved for issuance							238,095
2021 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, initially reserved for issuance	3,450,000
Minimum percentage of voting rights	10%
Minimum percentage of fair market value of exercise price for incentive and non-statutory stock options	110%
Vesting period	4 years
Common stock reserved for issuance, annual increase, beginning date	Jan. 01, 2022
Common stock reserved for issuance, annual increase, end date	Jan. 01, 2031
Percentage of annual increase in shares reserved for issuance based on common stock outstanding	5%
Number of shares available for issuance		3,780,239		3,780,239
2021 Equity Incentive Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expiration term	10 years
2021 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, initially reserved for issuance		685,317		685,317
Common stock reserved for issuance, annual increase, beginning date	Jan. 01, 2022
Common stock reserved for issuance, annual increase, end date	Jan. 01, 2031
ESPP offering periods description				There are two ESPP offering periods each year and the first offering period started on June 1, 2022. Each offering period has one purchase period which occurs every six months.
Percentage of annual increase in shares reserved for issuance based on common stock outstanding	1%
Shares authorized	4,703,469
Shares issued		0		0

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Stock Option Activity (Details) - 2012 and 2021 Plan $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Options Available for Grant
Outstanding at beginning of period	2,673,582
Authorized	1,676,587
Granted	(631,520)
Cancelled	61,590
Outstanding at end of period	3,780,239	2,673,582
Number of Options Outstanding
Outstanding at beginning of period	4,028,461
Granted	631,520
Exercised	(206,130)
Cancelled	(61,590)
Outstanding at end of period	4,392,261	4,028,461
Exercisable at end of period	1,527,275
Weighted-Average Exercise Price Per Share
Outstanding at beginning of period | $ / shares	$ 8.81
Granted | $ / shares	17.67
Exercised | $ / shares	2.29
Cancelled | $ / shares	19.65
Outstanding at end of period | $ / shares	10.24	$ 8.81
Exercisable at end of period | $ / shares	$ 3.58
Weighted-Average Remaining Contractual Life (years)
Outstanding	8 years 3 months	8 years 4 months 24 days
Exercisable	6 years 8 months 15 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value Outstanding | $	$ 26,189	$ 60,089
Exercisable at end of period | $	$ 15,328

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Estimated Grant-Date Fair Value of Stock-Based Awards Calculated Using Black-Scholes Option Pricing Model (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)		6 years 1 month 6 days
Expected volatility	77.10%	67.70%
Expected volatility, minimum			77.10%	67.70%
Expected volatility, maximum			78.10%	69.90%
Risk-free interest rate		1%
Risk-free interest rate, minimum	2.80%		1.70%	0.60%
Risk-free interest rate, maximum	3.30%		3.30%	1.10%
Expected dividend yield			0%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	5 years 6 months		5 years 6 months	5 years 10 months 24 days
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term (in years)	6 years 1 month 6 days		6 years 1 month 6 days	6 years 1 month 6 days

Stock-Based Compensation - Sc_3

Stock-Based Compensation - Schedule of Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 1,742	$ 434	$ 3,093	$ 753
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	710	131	1,363	188
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 1,032	$ 303	$ 1,730	$ 565

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0	$ 0	$ 0

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Potentially Dilutive Shares Including All Outstanding Stock Options Were Not Included in Calculation of Diluted Shares Outstanding (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive shares	4,392,261	24,606,693	4,392,261	24,606,693
Convertible Preferred Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive shares		21,435,632		21,435,632
Outstanding Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Potentially dilutive shares	4,392,261	3,171,061	4,392,261	3,171,061